StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a report released on Wednesday morning. The firm issued a sell rating on the stock.

Oragenics Stock Performance

OGEN opened at $0.40 on Wednesday. The firm has a market cap of $1.78 million, a price-to-earnings ratio of -0.05 and a beta of 0.50. The firm’s 50-day simple moving average is $0.92 and its 200-day simple moving average is $1.26. Oragenics has a twelve month low of $0.38 and a twelve month high of $7.74.

Oragenics (NYSE:OGEN) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new stake in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent SEC filing. 18.71% of the stock is owned by institutional investors and hedge funds.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.